Claudia Ortiz Lopez, PharmD Candidate Cone Health Family Medicine News You Can Use… Claudia Ortiz Lopez, PharmD Candidate Kelsy Combs, PharmD Pete Koval, PharmD Cone Health Family Medicine January, 2017

Brand-to-Generic Switch Tamiflu® is now available generically as oseltamivir phosphate Generic approved on 8/5/16, now available from Alvogen http://www.drugstorenews.com/article/alvogen-natco-launch-first-tamiflu-generic

Health Care Costs US Spending on Personal Health care and Public Health 1996-2013 Highest Health Care Annual Spending Diabetes $101.4 billion Ischemic Heart Disease $88.1 billion Low Back and Neck Pain $87.6 billion JAMA. 2016;316(24):2627-2646.

FDA Approval MACI (Matrix-induced autologous chondrocyte implantation) First FDA-approved product that uses tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee For the repair of symptomatic, full thickness cartilage defects of the knee in adult patients ADEs: joint pain, cold-like symptoms, headache, back pain http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533153.htm

Statins in Younger Patients New study showed low rates of statin prescription in younger patients with severe dyslipidemia (LDL >190 mg/dL) Statins prescribed per age group: 30-40 yo – 32% 40-50 yo – 47% 50-60 yo – 61% Rate of Statin Prescription in Younger Patients With Severe Dyslipidemia. JAMA Cardiol. Published online January 04, 2017.

FDA Labeling Addition Jardiance ® (empagliflozin) MOA: SGLT2 FDA adds new indication to reduce the risk of CV death in adult patients with type 2 diabetes and CV disease http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm

ADA 2017 update for Diabetes Recommendation added to consider empagliflozin (SGLT2) or liraglutide (GLP1) Median cost of noninsulin and insulin agents added Noninferiority of GLP1 vs rapid acting insulin vs twice daily premixed insulin in addition to basal insulin Diabetes Care 2017;40(Suppl. 1):S4–S5 Diabetes Care 2017;40(Suppl. 1):S64–S74

FDA Approval Spinraza® (nusinersen) Class: survival motor neuron-2 (SMN2) directed antisense oligonucleotide For the treatment of spinal muscular atrophy in pediatric and adult pateints Dose: 12 mg intrathecally x 4 loading doses then every 4 months ADE: respiratory infection, constipation http:// http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/100180/spinraza-nusinersen

FDA Approval Eucrisa® (crisaborole) Class: phosphodiesterase 4 (PDE-4) inhibitor For the treatment of mild to moderate eczema (atopic dermatitis) in patients ≥ 2 yo Dose: apply a thin layer of ointment twice daily ADE: application site pain, hypersensitivity reaction http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533371.htm